Phase 3 trial – Page 2

Repare Therapeutics Advances to Phase 3 Cancer Combo Trial Following Successful MYTHIC Trial Outcomes

3 months ago talkbio0Tagged camonsertib, cancer combo trial, cost-effective clinical trials, lunresertib, Malignant neoplasm of endometrium, MYTHIC, Phase 3 trial, Platinum-Resistant Ovarian Carcinoma, Repare

Repare Therapeutics, Phase 3 trial, cancer combo trial, MYTHIC trial, lunresertib, camonsertib, endometrial cancer, platinum-resistant ovarian cancer, cost-effective clinical trials

Tenpoint Therapeutics Announces Breakthrough Phase 3 Results for Presbyopia Treatment Following Merger with Visus

4 months ago talkbio0Tagged BRIMOCHOL, Eye, fluorouracil/melphalan, Phase 3 trial, presbyopia, Tenpoint Therapeutics, vision drug, Visus merger

Tenpoint Therapeutics, Visus merger, Phase 3 trial, presbyopia treatment, BRIMOCHOL PF, vision drug, ophthalmic therapeutics

Novartis Achieves Pivotal Trial Success for Intrathecal Zolgensma in Older SMA Patients After FDA Delay

4 months ago talkbio0Tagged Approved, intrathecal formulation, Novartis, older, Phase 3 trial, Spinal Muscular Atrophy, United States Food and Drug Administration, Zolgensma

Novartis, Zolgensma, Intrathecal formulation, Spinal muscular atrophy (SMA), FDA approval, Pivotal phase 3 trial, Older SMA patients

Neumora’s Navacaprant Fails to Meet Expectations in First Phase 3 Trial for Major Depressive Disorder

4 months ago talkbio0Tagged Clinical Research, KOASTAL-1, navacaprant, Neumora, Phase 3 trial

Neumora Therapeutics, Navacaprant, Major Depressive Disorder, Phase 3 Trial, KOASTAL-1 Study

Merck’s Investigational ADC Zilovertamab Vedotin Enters Phase 3 with 100% Complete Response Rate in DLBCL Patients

5 months ago talkbio0Tagged Antibody-Drug Conjugates, Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Phase 2 trial, Phase 3 trial, Programs - Publication Format, ROR1 protein, human, vedotin, Zilovertamab

Zilovertamab Vedotin, Antibody-Drug Conjugate (ADC), Diffuse Large B-Cell Lymphoma (DLBCL), Phase 2 Trial, Phase 3 Trial, ROR1, Merck, waveLINE Program

Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial

5 months ago talkbio0Tagged Keytruda, Malignant neoplasm of lung, Overall Survival, Phase 3 trial, Roche (company), Skyscraper-01, Tecentriq, TIGIT gene, Tiragolumab

Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq

Biohaven’s Taldefgrobep Alfa Shifts Focus to Obesity After Missing Primary Endpoint in Spinal Muscular Atrophy Phase 3 Trial

5 months ago talkbio0Tagged Alfa, Body Composition, Bone and Bones, density, GDF8 protein, human, Inhibitor, lean, Obesity, Phase 3 trial, Spinal Muscular Atrophy

Biohaven, taldefgrobep alfa, spinal muscular atrophy (SMA), obesity, myostatin inhibitor, phase 3 trial, body composition, lean muscle mass, bone density.

Incyte Unveils Promising Monjuvi Data at ASH24, Paving Way for FDA Label Expansion in Follicular Lymphoma

5 months ago talkbio0Tagged ASH24, expansion, Incyte, Lymphoma, Follicular, Monjuvi, Phase 3 trial, United States Food and Drug Administration

Incyte, Monjuvi, ASH24, Follicular Lymphoma, Label Expansion, FDA, Phase 3 Trial

AstraZeneca’s Truqap Achieves Phase 3 Success in Prostate Cancer, Paving Way for Label Expansion

5 months ago talkbio0Tagged Antiandrogen therapy, AstraZeneca, CAPItello-281, Hormone Responsive, Malignant neoplasm of prostate, Metastatic to, Phase 3 trial, Progression-Free Survival, PTEN-deficient, Radiographic, rPFS, Truqap

AstraZeneca, Truqap, prostate cancer, Phase 3 trial, CAPItello-281, PTEN-deficient, metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT)

Biohaven’s Taldefgrobep Alfa Misses Primary Endpoint in Phase 3 SMA Trial, Eyes FDA Discussions and Obesity Indication

5 months ago talkbio0Tagged Discussion (procedure), Indication of (contextual qualifier), Obesity, Phase 3 trial, Spinal Muscular Atrophy, Talditercept alfa, United States Food and Drug Administration

Biohaven, Taldefgrobep Alfa, Spinal Muscular Atrophy (SMA), Phase 3 Trial, FDA Discussions, Obesity Indication